The knock-on effects of these cuts has also seen an increase of over 61,000 hospital admissions since 2012 at an estimated cost of £317m to the NHS.
The knock-on effects of these cuts has also seen an increase of over 61,000 hospital admissions since 2012 at an estimated cost of £317m to the NHS.
84% of Brits fear losing their sight more than any other sense.
Earlier this week Sensyne announced a formal research agreement with the MHRA.
The recommendation comes after Consilient Health agreed a Patient Access Scheme with NICE.
The partnership will focus on developing potent Affimer-drug conjugates.
The Stop MS Appeal aims to raise the funds over ten years to find treatments for everyone living with the progressive, immune-mediated disorder.
The drug achieved complete control of hives in 51% and 42% of patients, compared with 26% of patients treated with Xolair.
This year’s awards ceremony will be taking place at the Chelsea Harbour Hotel on the 14th November.
The scheme will offer practical support to any doctor, nurse, or other worker across the country who needs additional support to build their career after raising concerns at work.
The partnership will develop new technologies to improve cell therapies for cancer patients.
There are no approved drugs at current for preventing or slowing disease progression.
Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations.
Samsung Bioepis has announced real-world data from the drug.
Jane Thomson of PRA Health Sciences shares why clinical researchers from across the globe should enter into the 2020 competition.
The three-year signature initiative is designed to make learning about health and disease engaging, accessible, and exciting for students in grades six to eight.